Bertrand Delsuc
@BertrandBio
Followers
19K
Following
22K
Media
12K
Statuses
92K
Views=mine only, RT-like=/=endorse, no advice. 16y in Tech (chip design) & 10y following bios. Preplanned pause.
Lyon, France
Joined April 2015
Hi all, I plan to be in London around the dates of the HC investor events there (17-20 Nov). DM open if you want to get in touch. Cheers!
7
1
23
Just a little thread, out of my retreat, because this stock and its story has been important to me. Maybe a mini-victory lap as well, but with quite some general learnings overall, and hard ones. I have been long $ABVX since the disclosure of the POC data in UC in September 2018
15
11
203
🇨🇳Kelun-Biotech Announces Approximately US$250 Million Placement #ADC
prnewswire.com
/PRNewswire/ -- On June 5, 2025, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced the placement of...
1
0
5
Useful slide to explain clinical outcomes for pts with 1st line, 2nd line and Beyond For HR+ /Her2 -ve MBC . Money 💰 slide by @jhaveri_komal @asco #asco25 @OncoAlert @OncBrothers
7
58
209
Quickly and easily evaluate borrowers' income with our award-winning Income Calculator. Let our technology work harder for you, so you can do great work for your borrowers. Learn more.
2
16
138
Catching up on some #ASCO25 sessions, I came across this on dual-payload ADCs from Patricia LoRusso's clinical science symposium
3
10
23
another positive "less is more" trial good that such studies are featured in the NEJM
In oncology, we don’t usually love overlapping Kaplan-Meier curves. Except that sometimes we really do. Thanks to NSABP-B51, countless pts will be spared the toxicity of nodal irradiation, and many will live free from a permanent lymph edema that would have impacted their lives.
1
0
5
outside the numerous insights from #ASCO25, interesting update on pot. WH move in favor of allowing pharma to adopt a rebate model re: 340B program (would be a +ve for bigP), in the next weeks or months
Listen to Deep ASCO Review; BioNTech & Regeneron Deals: BI Drug Call; Bloomberg Intelligence #np on #SoundCloud
https://t.co/ZPwn3lfitG $REGN $HNSPF $JNJ $BNTX $BMY $SMMT $TIL $PFE $TRSBF $AKESF $AZN $IVBXF $RHHBY $JAZZ $AMGN $ZYME $RVMD $DSNKY $GILD $MRK $RCUS $LEGN $MRUS $BCAX
0
0
1
This is the gift. USDA Prime steaks. Gold box. Dry ice unboxing. Delivered by Christmas. They'll remember who sent it. 6 FREE Petite Ribeyes + FREE shipping ($240 value) on $229+ orders Code SANTA229 🥩
0
2
7
Truth Social has crashed from the traffic surge and in so doing accidentally created a hauntingly poignant image.
677
26K
242K
$AZN #ASCO25 deck (correct link - prior one was the Q4'24/FY'24 earnings) https://t.co/kmx4F20RBH
1
0
3
Since 2000, hospital prices have soared by over 250% – 3x the rate of inflation. Why? Mergers and consolidation give them more power to set prices. It’s time to hold hospitals accountable for rising health care costs. Learn more.
7
13
59
$AZN S. Galbraith said (if I got it well - not warranted) that the discrepancy comes from the fact there is a delay between the INV assessment and the BICR assessment for PFS (BICR after INV), and the fact some pts in the control arm possibly unblinded themselves, were
astrazeneca.com
Our latest results announcements and presentations include regular updates covering pipeline reports, earnings and revenue data from across the business.
1
0
0
as mentioned in $AZN #ASCO25 call, carboplatin is usually more tolerated than cisplatin that might explain this effect seen in CM-816
0
0
0
REGENXBIO $RGNX REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE TRIAL OF RGX-202 https://t.co/ejvMfPXsIy
1
0
11
$CGEM another chyna deal tce-bcma https://t.co/6eRF4qunF3
investors.cullinantherapeutics.com
Advances Cullinan’s leadership in T cell engager (TCE) development for autoimmune diseases with both a CD19 TCE and BCMA TCE in its pipeline Strengthens Cullinan portfolio of autoimmune programs with...
2
1
18